The spread of counterfeit anti-obesity and diabetes drugs is growing across the European Union due to high prices and shortages of originals.[1][2][4] In recent months, European authorities have noticed a sharp increase in the supply of these drugs, which fraudsters pass off as GLP-1 receptor agonists.[1][2][4] Counterfeits contain active substances such as semaglutide, liraglutide and tirzepatide, sold under different names through fraudulent websites and social networks.[2][4][6] ŠÚKL warns that these unapproved drugs may contain dangerous or even life-threatening substances, which threatens patients with serious health problems and interactions with other drugs.[1][2][5] Authorities have uncovered hundreds of fake Facebook profiles and online stores, many based outside the EU, misusing official logos.[1][2] In Britain, police seized more than 2,000 fake doses of tirzepatide and retatrutide, equipment, chemicals and £20,000 in cash with an estimated black market value of £250,000 from a factory.[3] These drugs are subject to a prescription and must be taken under the supervision of a physician.[1]